Clinical Trials Sponsored by Barc NV

Total 1299 results

Galapagos NV

Completed

First-in-Human Single Ascending and Multiple Dose of GLPG0259

Healthy

Belgium
Galapagos NV

Completed

First-in-Human Single Ascending and Multiple Dose of GLPG0778

Healthy

Belgium
Galapagos NV

Completed

First-in-Human Single Ascending and Multiple Dose of GLPG0634

Healthy

Belgium
Galapagos NV

Completed

Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of GLPG0555 in Healthy Subjects

Healthy

Belgium
Galapagos NV

Completed

First-in-Human Single Ascending and Multiple Dose of GLPG0555

Healthy

Belgium
Galapagos NV

Recruiting

Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC) (GALOCEAN)

Ulcerative Colitis

Belgium, Netherlands, France, Italy, Germany, Norway, United Kingdom, Ireland, Austria
Oystershell NV

Completed

Clinical Trial to Evaluate Efficacy and Safety of a Cryogenic Medical Device for Treatment of Common and Plantar Warts

Warts

Poland
Galapagos NV

Completed

First-in-Human Single Ascending Dose of GLPG0492

Healthy

Belgium
Galapagos NV

Completed

Drug-drug Interaction Study With GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects

Healthy

Germany
Galapagos NV

Completed

A Study to Evaluate How Well Single and Multiple Doses of GLPG3121-modified Release Formulation Are Tolerated in Healthy, Adult Subjects

Healthy

Germany
Galapagos NV

Completed

A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970

Healthy | Psoriasis

Belgium, Moldova, Republic of, Ukraine
Galapagos NV

Completed

A Study to Assess Relative Bioavailability of and Effect of Food on a New Oral Tablet Formulation of GLPG3970

Healthy

France
Galapagos NV

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Healthy Japanese and Caucasian Male Subjects

Healthy

United States
Galapagos NV

Completed

Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)

Rheumatoid Arthritis

New Zealand, Colombia, Australia, Romania, United States, Bulgaria, Germany, Latvia, Mexico, Moldova, Republic of, Poland, Spain, Argentina, Austria, Chile, Guatemala, Hungary, Russian Federation, Ukraine
Qompium NV

Completed

Qualitative Analysis of Photoplethysmography Waveforms for the Detection of Cardiac Arrhythmias (INTERPRET-AF I)

Cardiac Arrhythmia

Belgium
Galapagos NV

Completed

Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1) (DARWIN1)

Rheumatoid Arthritis

France, Spain, New Zealand, Belgium, Israel, Chile, United States, Colombia, Germany, Australia, Poland, Hungary, Russian Federation, Mexico, Argentina, Bulgaria, Czechia, Guatemala, Latvia, Moldova, Republic of, Ukraine, Austria
Galapagos NV

Completed

Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

United Kingdom, Ukraine
Galapagos NV

Terminated

A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a Study Drug Called MOR106, in Healthy Subjects and in Patients With Moderate to Severe Atopic Dermatitis

Healthy | Atopic Dermatitis

Spain, Germany, Ukraine, United Kingdom
Galapagos NV

Completed

A Study in Healthy Volunteers to Compare Different Tablet Formulations of the Test Medicine, GLPG1972, Against the Current Tablet Formulation, and to Assess the Effect Food Has on One of the Test Medicines

Healthy

United Kingdom
Ectosense NV

Unknown

NightOwl SpO2 Calibration Study (NOSCS)

Pulse Oximeter Calibration

Belgium
Ectosense NV

Unknown

NightOwl Pulse Oximeter Calibration Study (NPOCS)

Pulse Oximeter Calibration

Belgium
Galapagos NV

Completed

A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Given by Mouth and Into a Vein as an Injection

Healthy

United Kingdom
Galapagos NV

Completed

A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis

Cystic Fibrosis

Spain, United Kingdom, United States, Netherlands, Belgium, Serbia
Galapagos NV

Completed

Pharmacokinetics of GLPG3067 in Male Subjects With Cystic Fibrosis.

Cystic Fibrosis

Belgium
FLUIDDA nv

Terminated

Evaluation of the Effect of Roflumilast in Hyperinflated COPD Patients Using Functional Respiratory Imaging

Pulmonary Disease, Chronic Obstructive

Belgium
Galapagos NV

Completed

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects

Healthy

Netherlands
Galapagos NV

Completed

A Study With GLPG1972 in Osteoarthritis Subjects

Osteoarthritis

United States
Galapagos NV

Completed

Study to Assess Bioavailability of GLPG1690 Given as Oral Capsule or Tablet

Healthy

Belgium
Galapagos NV

Terminated

Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)

Clinically Isolated Syndrome | Acute Exacerbation of Remitting Relapsing Multiple Sclerosis

Belgium, Poland, Germany
Galapagos NV

Completed

A Drug-drug Interaction Study Between GLPG1205 and a Cocktail of CYP450 Substrates in Healthy Male Subjects

Healthy

Belgium
Galapagos NV

Completed

Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease

Crohn's Disease

United Kingdom, Belgium, France, Hungary, Russian Federation, Czech Republic, Germany, Poland, Romania
Galapagos NV

Completed

Efficacy and Safety of GLPG1205 in Subjects With Active Ulcerative Colitis (ORIGIN)

Ulcerative Colitis

Belgium, Czech Republic, Germany, Hungary, Poland, Russian Federation
Galapagos NV

Completed

First-in-Human Single and Multiple Dose of GLPG1837

Healthy

Belgium
Amakem, NV

Completed

Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma | Eye Disease

United States
Galapagos NV

Completed

Multiple Ascending Dose Study of GLPG0634 in Japanese and Caucasian Healthy Subjects

Healthy

United Kingdom
Galapagos NV

Completed

Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects

Renal Impairment

Germany
FLUIDDA nv

Completed

Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients

Asthma

Belgium
FLUIDDA nv

Completed

Evaluation With CT Scan of Possible Changes in Airways After Treatment With Daxas® in Severe Chronic Obstructive Pulmonary Disease Patients

Pulmonary Disease, Chronic Obstructive

Belgium
Galapagos NV

Completed

Oral Bioavailability of Two Solid Formulations of GLPG0634

Healthy

Belgium
Galapagos NV

Completed

GLPG0187: Safety, Tolerability and Pharmacokinetics in Patients With Solid Tumors

Solid Tumors

Netherlands
Galapagos NV

Completed

A Phase I, Open Interaction Study Between GLPG0634 and Midazolam in Healthy Subjects

Healthy

United States
Galapagos NV

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of GLPG0634 in Healthy Subjects

Healthy

Belgium
Galapagos NV

Completed

Bioavailability Study of Prodrug of GLPG0187 in Healthy Volunteers

Healthy

Belgium
Galapagos NV

Completed

GLPG0492 Pharmacodynamics

Healthy

Belgium
Galapagos NV

Completed

Multiple Ascending Dose Study of GLPG0492 in Healthy Subjects

Healthy

Germany
Galapagos NV

Completed

Oral Bioavailability of GLPG0555 in Different Solid Formulations

Healthy

Belgium
Galapagos NV

Completed

GLPG0259 Solid Formulation Bioavailability and Food Effect

Healthy

Belgium
Fugeia NV

Completed

In Vivo Evaluation of the Physiological Effects of Arabinoxylan-oligosaccharides (AXOS) in Healthy Subjects (Adults)

Healthy

Belgium
Qompium NV

Recruiting

FibriCheck Data Registry (FDR)

Cardiac Arrhythmia

Belgium
Qompium NV

Recruiting

Fibricheck Detection cApabilities for Atrial Fibrillation (FDA-AF)

Atrial Fibrillation

United States, Belgium

3

Subscribe